Medication info
Emparilduo Extended-Release Tablets 10/1000 mg (Empagliflozin, Metformin)

Emparilduo Extended-Release Tablets 10/1000 mg (Empagliflozin, Metformin)

Prescription medicationTabletOral
Ingredient · strength
Empagliflozin›10mg / 1 tabletMetformin Hydrochloride›1000mg / 1 tablet
Manufacturer / importer
Aju Pharmaceuticals Co., Ltd.
Appearance
Yellow rectangular extended-release film-coated tablet
Packaging
Bottle packaging - 30 tablets/bottle
Approval status
Active

MFDS item code 202501595 · Approved 2025.06.27 · Insurance code 654006260

Summary

Main use
Improvement of blood glucose control in adults with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
For antidiabetic therapy, determine the dose of this medicine based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: empagliflozin 25mg and metformin hydrochloride extended-release 2000 mg. To reduce gastrointestinal adverse reactions caused by metformin, take this medicine once daily in the evening with a meal. Take 1 tablet of this medicine 10/1000 mg extended-release tablet or 25/1000 mg extended-release tablet once daily. Patients taking this medicine 5/1000 mg extended-release tablet or 12.5/1000 mg extended-release tablet should take 2 tablets at the same time once daily. To reduce gastrointestinal adverse reactions associated with metformin use, the dose of metformin hydrochloride should be increased gradually. To maintain its extended-release properties, swallow this medicine whole; do not split, crush, grind, or chew it. This medicine may not dissolve completely and may be excreted in the feces. It is not known whether the material excreted in the feces contains the active ingredients of the medicine. If a patient repeatedly reports finding this medicine in the feces, healthcare professionals should evaluate whether blood glucose is being adequately controlled (see Precautions for Use, 5. General Precautions). For patients whose blood glucose is not adequately controlled with metformin alone or in combination with other medicines such as insulin, the recommended initial total daily dose when starting this medicine is empagliflozin 10 mg and the patient's existing metformin dose. If the patient tolerates empagliflozin 10 mg well but requires additional glycemic control, the dose may be increased to empagliflozin 25 mg. Patients switching from concomitant therapy with empagliflozin and metformin to this medicine should receive their existing doses of empagliflozin and metformin. When switching from immediate-release metformin to the extended-release formulation, glycemic control should be closely monitored and the dose adjusted appropriately. When this medicine is coadministered with a sulfonylurea or insulin, a dose reduction of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia (see Precautions for Use, 4. Adverse Reactions and 6. Interactions). As dose adjustment according to renal function is necessary, assessment of renal function is recommended before starting this medicine and periodically thereafter. No dose adjustment of this medicine is necessary in patients with mild renal impairment [creatinine clearance (CrCl) ≧ 60 mL/min or estimated glomerular filtration rate (eGFR) ≧ 60 mL/min/1.73 m2]. In patients with moderate renal impairment [CKD stage 3A, creatinine clearance (CrCl) ≧ 45 mL/min and <60mL/min or estimated glomerular filtration rate (eGFR) ≧ 45 mL/min/1.73m2 and <60mL/min/1.73m2] who tolerate treatment well and have no other conditions that may increase the risk of lactic acidosis, this medicine may be used with adjustment of the metformin hydrochloride dose as follows. - The starting dose of extended-release metformin hydrochloride is 500 mg or 750 mg once daily; therefore, treatment should not be initiated with this medicine. The maximum daily dose of metformin hydrochloride is 1000mg. If creatinine clearance (CrCl) decreases to less than 45 ml/min or estimated glomerular filtration rate (eGFR) decreases to less than 45 ml/min/1.73m2, this medicine should be discontinued immediately. In patients 75 years of age and older, renal function and the risk of volume depletion should be considered.

Ingredients

Manufacturer
Aju Pharmaceuticals Co., Ltd.

Efficacy & effects

Improvement of blood glucose control in adults with type 2 diabetes mellitus

  • Blood glucose control issues
  • cardiovascular diseases
  • cardiovascular events
View approved original text

This medication effectively improves blood glucose control in adult patients with type 2 diabetes when used in combination with dietary and exercise therapy alongside the administration of empagliflozin and metformin. Special attention should be paid to patients with cardiovascular diseases among those whose blood glucose is not adequately controlled.

How to take

Adult dose

For antidiabetic therapy, determine the dose of this medicine based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: empagliflozin 25mg and metformin hydrochloride extended-release 2000 mg. To reduce gastrointestinal adverse reactions caused by metformin, take this medicine once daily in the evening with a meal. Take 1 tablet of this medicine 10/1000 mg extended-release tablet or 25/1000 mg extended-release tablet once daily. Patients taking this medicine 5/1000 mg extended-release tablet or 12.5/1000 mg extended-release tablet should take 2 tablets at the same time once daily. To reduce gastrointestinal adverse reactions associated with metformin use, the dose of metformin hydrochloride should be increased gradually. To maintain its extended-release properties, swallow this medicine whole; do not split, crush, grind, or chew it. This medicine may not dissolve completely and may be excreted in the feces. It is not known whether the material excreted in the feces contains the active ingredients of the medicine. If a patient repeatedly reports finding this medicine in the feces, healthcare professionals should evaluate whether blood glucose is being adequately controlled (see Precautions for Use, 5. General Precautions). For patients whose blood glucose is not adequately controlled with metformin alone or in combination with other medicines such as insulin, the recommended initial total daily dose when starting this medicine is empagliflozin 10 mg and the patient's existing metformin dose. If the patient tolerates empagliflozin 10 mg well but requires additional glycemic control, the dose may be increased to empagliflozin 25 mg. Patients switching from concomitant therapy with empagliflozin and metformin to this medicine should receive their existing doses of empagliflozin and metformin. When switching from immediate-release metformin to the extended-release formulation, glycemic control should be closely monitored and the dose adjusted appropriately. When this medicine is coadministered with a sulfonylurea or insulin, a dose reduction of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia (see Precautions for Use, 4. Adverse Reactions and 6. Interactions). As dose adjustment according to renal function is necessary, assessment of renal function is recommended before starting this medicine and periodically thereafter. No dose adjustment of this medicine is necessary in patients with mild renal impairment [creatinine clearance (CrCl) ≧ 60 mL/min or estimated glomerular filtration rate (eGFR) ≧ 60 mL/min/1.73 m2]. In patients with moderate renal impairment [CKD stage 3A, creatinine clearance (CrCl) ≧ 45 mL/min and <60mL/min or estimated glomerular filtration rate (eGFR) ≧ 45 mL/min/1.73m2 and <60mL/min/1.73m2] who tolerate treatment well and have no other conditions that may increase the risk of lactic acidosis, this medicine may be used with adjustment of the metformin hydrochloride dose as follows. - The starting dose of extended-release metformin hydrochloride is 500 mg or 750 mg once daily; therefore, treatment should not be initiated with this medicine. The maximum daily dose of metformin hydrochloride is 1000mg. If creatinine clearance (CrCl) decreases to less than 45 ml/min or estimated glomerular filtration rate (eGFR) decreases to less than 45 ml/min/1.73m2, this medicine should be discontinued immediately. In patients 75 years of age and older, renal function and the risk of volume depletion should be considered.

Precautions

This medication is primarily used for diabetes treatment and helps in controlling blood sugar levels. However, there are several precautions to take while using this medicine. Firstly, this medication can rarely cause a serious condition called lactic acidosis, which is more likely to occur in patients with reduced kidney function or those who are dehydrated or have severe infections. Additionally, symptoms of hypoglycemia may occur when taken with insulin or sulfonylureas, so blood glucose levels should be monitored closely. This medication should not be administered to patients with moderate to severe kidney function impairment, acute heart failure, acute infections, dehydration, or pregnant women. Before and after undergoing tests involving iodine contrast agents, the administration of this medication should be temporarily halted until kidney function returns to normal. During treatment, side effects such as hypoglycemia, urinary tract infections, genital infections, increased urination, nausea, vomiting, diarrhea, abdominal pain, loss of appetite, constipation, reduced vitamin B12, taste disturbances, itching, rash, erythema, hives, angioedema, diagnostic test abnormalities (increased serum creatinine, decreased glomerular filtration rate), thirst, increased serum lipids, weight loss, headache, dizziness, weakness, chest discomfort, chest pain, insomnia, vulvar pruritus, and genital discomfort may occur, so immediate consultation with medical staff is necessary if any of these symptoms arise. Furthermore, as vitamin B12 levels may decrease, it is advisable to regularly check blood levels. Alcohol consumption may increase the risk of lactic acidosis; therefore, it is important to avoid excessive drinking during treatment. Elderly patients may have a higher risk of decreased kidney function, so kidney function tests should be conducted before treatment, followed by regular monitoring. This medication should be swallowed whole without crushing or chewing, and it may sometimes pass through the stool intact, which is considered normal. Finally, this medication can interact with various other drugs, so if other medications are being taken, it is necessary to inform medical personnel.

Side effects

  • Hypoglycemia
  • urinary tract infection
  • genital infection
  • increased urination
  • decreased vitamin B12 and deficiency
  • ketoacidosis
  • lactic acidosis
  • reduced fluid volume
  • nausea
  • vomiting
Show 146 more
  • diarrhea
  • abdominal pain
  • loss of appetite
  • constipation
  • abnormal liver function tests
  • hepatitis
  • altered taste
  • pruritus
  • rash
  • urticaria
  • erythema
  • angioedema
  • dysuria
  • interstitial nephritis
  • thirst
  • increased serum lipids
  • elevated serum creatinine
  • decreased glomerular filtration rate
  • increased hematocrit
  • perineal necrosis
  • chronic gastritis
  • cerebral infarction
  • soft tissue infection
  • pneumonia
  • ankle fracture
  • epicondylitis
  • facial bone fracture
  • musculoskeletal pain
  • myocardial infarction
  • pancreatic carcinoma
  • diarrhea
  • nausea
  • gastric ulcer
  • colitis
  • ischemic colitis
  • bowel hemorrhage
  • appendiceal abscess
  • appendicitis
  • meningitis
  • chronic otitis media
  • peritonsillar abscess
  • pulmonary tuberculosis
  • sepsis
  • subcutaneous abscess
  • tubo-ovarian abscess
  • vestibular neuritis
  • headache
  • positional dizziness
  • asthenia
  • chest discomfort
  • chest pain
  • increased alanine aminotransferase
  • increased aspartate aminotransferase
  • urinary stones
  • hematuria
  • hypertonic bladder
  • renal mass
  • urinary retention
  • urinary pain
  • abnormal urination
  • vulvar pruritus
  • benign prostatic hyperplasia
  • cervical inflammation
  • hyperglycemia
  • hyponatremia
  • dermal cyst
  • seborrheic dermatitis
  • atopic dermatitis
  • diabetic foot
  • nummular eczema
  • heat rash
  • sebaceous gland hyperplasia
  • lumbar spinal canal stenosis
  • myalgia
  • limb pain
  • musculoskeletal chest pain
  • arthralgia
  • cervical stenosis
  • fibromyalgia
  • flank pain
  • fracture pain
  • muscle weakness
  • osteoarthritis
  • osteoporosis
  • rotator cuff syndrome
  • astigmatism
  • cataract
  • allergic conjunctivitis
  • blurred vision
  • corneal erosion
  • glaucoma
  • macular fibrosis
  • eye discomfort
  • conjunctival injection
  • pathological myopia
  • retinal detachment
  • retinal crystals
  • retinal vein occlusion
  • macular retinal detachment
  • eyelid swelling
  • visual impairment
  • vitreous floaters
  • vitreous hemorrhage
  • epistaxis
  • asthma
  • exertional dyspnea
  • wet cough
  • allergic rhinitis
  • residual sputum
  • skin laceration
  • contusion
  • rib fracture
  • concussion
  • corneal abrasion
  • falls
  • hand fracture
  • iliotibial band syndrome
  • open globe injury
  • pelvic fracture
  • road traffic accident
  • splenic injury
  • sternum fracture
  • angina pectoris
  • palpitations
  • Prinzmetal angina
  • coronary artery disease
  • tachycardia
  • atherosclerosis
  • deep vein thrombosis
  • diabetic vascular complications
  • peripheral arterial occlusive disease
  • anxiety
  • depression
  • sleep disorders
  • acute cholecystitis
  • autoimmune hepatitis
  • cholelithiasis
  • hepatitis
  • otalgia
  • positional vertigo
  • dizziness
  • anemia
  • lymphadenopathy
  • hypothyroidism
  • thyroid nodule
  • insomnia

Not everyone experiences these, and they can vary from person to person.

Storage

This medication can be sensitive to air or moisture and should be stored in a tightly sealed container. It is important to maintain a storage temperature between 1 and 30 degrees Celsius. This will help preserve the medication's effectiveness.

Appearance and packaging

Appearance

Yellow rectangular extended-release film-coated tablet

Package unit

Bottle packaging - 30 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.